论文部分内容阅读
目的:探讨乳腺癌患者加用重组人粒细胞集落刺激因子(rh G-CSF)骨髓支持治疗的临床效果。方法:将我院2011年1月-2012年12月收治的106例乳腺癌患者随机分为对照组及观察组,每组53例。两组均给予常规化疗治疗,观察组在此基础上加用rh G-CSF骨髓支持治疗,比较两组治疗前后血象变化及骨髓毒性反应情况。结果:对照组治疗后WBC、ANC、Plt及Hb与治疗前比较均有显著降低,且差异具有统计学意义(P<0.05);而观察组治疗后以上血象指标较治疗前变化不明显(P>0.05),但与对照组同期比较具有显著性差异(P<0.05);观察组骨髓毒性反应较对照组轻,Ⅱ度以上发生率为26.42%,显著低于对照组的47.17%(P<0.05)。结论:乳腺癌患者加用rh G-CSF骨髓支持治疗可明显缓解患者化疗后的骨髓抑制反应,减少其骨髓毒性反应发生,对化疗导致白细胞数减少具有较好的预防和临床应用价值,值得进一步推广和应用。
Objective: To investigate the clinical effects of rhG-CSF in patients with breast cancer treated with bone marrow support. Methods: 106 cases of breast cancer admitted to our hospital from January 2011 to December 2012 were randomly divided into control group and observation group, with 53 cases in each group. The two groups were given conventional chemotherapy, the observation group on this basis with rhG-CSF bone marrow support therapy, compared before and after treatment of blood changes in both groups and bone marrow toxicity. Results: The WBC, ANC, Plt and Hb in the control group were significantly lower than those before treatment (P <0.05), while those in the control group were not significantly different from those before treatment (P > 0.05), but there was a significant difference compared with the control group (P <0.05). The bone marrow toxicity in the observation group was lighter than that in the control group, the incidence was more than Ⅱ degree (26.42%), which was significantly lower than that of the control group (47.17% 0.05). CONCLUSIONS: Bone marrow supportive therapy with rhG-CSF in patients with breast cancer can significantly relieve the bone marrow suppression response after chemotherapy and reduce the occurrence of myelotoxic reactions, which is of great value in the prevention and clinical application of chemotherapy to reduce the number of leukocytes, which is worth further Promotion and application.